Alzheimer’s disease
Speech biomarkers for long disease‑modifying AD trials
Disease-modifying AD trials follow small changes on slow endpoints over long studies.
Interpretable acoustic-linguistic and cognitive-linguistic features, with deep-learning embeddings alongside, with one architecture across languages and across the length of the study.
Where the reading lands
From the trial's cognitive scales to what Cephalgo reads
The scales an Alzheimer's program already administers, the parts of them scored from what the participant says, and the reading Cephalgo returns on each total score.
The scale
MMSE · MoCA
Cognitive tests the program already administers.
The reading
Between scheduled visits
A reading on the MMSE and MoCA from a short recording.
In practice
Short spoken tasks, read on the MMSE and MoCA
The tasks
Customised to your cohort
For example: picture description, reading aloud and short free speech. Tasks and their number are set for each cohort.
Where
At home or in clinic
On the participant's own device, with an automatic quality check at capture.
The output
Between scheduled visits
A reading on the MMSE and MoCA at every session, followed between visits.
In the trial
Built for real‑world clinical trials
Objective and automated
The same scoring everywhere
Every site and every visit is scored the same way, with no rater in the loop.
On the trial's scale
Readings on the MMSE and MoCA
Each reading lands on the scale the protocol already carries.
Robust
Limits drift when processing changes
Recalibrated from the recordings when on-device processing changes. How it works
Patient-centric
A couple of minutes at home
On the participant's own phone, tablet or computer, between scheduled visits.
Transparent and trackable
Visible per session
Completion, recording quality and versions are logged with every session.
Integrated
No new visit, no new rater
Runs on the Cephalgo platform alongside the assessments the study already runs.
Evidence
Validation following DiMe V3
Following the Digital Medicine Society’s V3 framework.
Clinical validation
Cognitive tests
Readings evaluated against the administered MMSE and MoCA, and Alzheimer's separated from MCI, on held‑out participants.
Across languages
One architecture
Evaluated in Spanish, English and Slovak.
Publications
Published and presented
White paper
Speech-Based Assessment in Alzheimer's Disease and MCI
Request the white paper
ePoster · AD/PD 2026
Validation of fully explainable speech biomarkers for AD/MCI screening
AD/MCI against healthy controls.
Contact
Where would speech sit in your next AD protocol?
Tell us about the studies you’re running and the questions you want speech to answer.
Get in touch →